GoodRx (NASDAQ:GDRX) Trading Down 5.1% – Time to Sell?

GoodRx Holdings, Inc. (NASDAQ:GDRX)’s stock price was down 5.1% on Wednesday . The stock traded as low as $3.60 and last traded at $3.6050. Approximately 459,413 shares changed hands during mid-day trading, a decline of 78% from the average session volume of 2,102,723 shares. The stock had previously closed at $3.80.

Wall Street Analysts Forecast Growth

GDRX has been the subject of several research reports. Wells Fargo & Company lifted their price objective on shares of GoodRx from $3.50 to $5.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Citigroup boosted their target price on shares of GoodRx from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Tuesday. Leerink Partners set a $5.00 price target on shares of GoodRx in a report on Thursday, August 6th. TD Cowen increased their price target on GoodRx from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Weiss Ratings raised GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 7th. Four analysts have rated the stock with a Buy rating, six have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.14.

GoodRx Price Performance

The company has a debt-to-equity ratio of 0.74, a current ratio of 1.38 and a quick ratio of 1.38. The stock has a fifty day simple moving average of $3.01 and a 200-day simple moving average of $2.58. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of 93.02, a P/E/G ratio of 1.70 and a beta of 1.60.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.08 EPS for the quarter, hitting analysts’ consensus estimates of $0.08. The business had revenue of $200.41 million for the quarter, compared to analysts’ expectations of $193.23 million. GoodRx had a net margin of 2.07% and a return on equity of 7.22%. The business’s revenue was down 1.3% on a year-over-year basis. During the same quarter last year, the company earned $0.09 EPS. On average, equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.16 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Essential Partners LLC boosted its stake in shares of GoodRx by 375.4% during the 1st quarter. Essential Partners LLC now owns 14,304 shares of the company’s stock worth $28,000 after acquiring an additional 11,295 shares in the last quarter. Meridian Wealth Management LLC purchased a new position in GoodRx during the fourth quarter worth approximately $29,000. SG Americas Securities LLC acquired a new stake in GoodRx in the first quarter valued at approximately $29,000. Krilogy Financial LLC acquired a new position in shares of GoodRx during the 1st quarter worth approximately $33,000. Finally, Quarry LP purchased a new position in shares of GoodRx during the 3rd quarter valued at approximately $33,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.